Abstract:Since development of plasmid gene therapy for therapeutic angiogenesis by J. Isner this approach was an attractive option for ischemic diseases affecting large cohorts of patients. However, first placebo-controlled clinical trials showed its limited efficacy questioning further advance to practice. Thus, combined methods using delivery of several angiogenic factors got into spotlight as a way to improve outcomes. This study provides experimental proof of concept for a combined approach using simultaneous delivery of VEGF165 and HGF genes to alleviate consequences of myocardial infarction (MI). However, recent studies suggested that angiogenic growth factors have pleiotropic effects that may contribute to outcome so we expanded focus of our work to investigate potential mechanisms underlying action of VEGF165, HGF and their combination in MI. Briefly, Wistar rats underwent coronary artery ligation followed by injection of plasmid bearing VEGF165 or HGF or mixture of these. Histological assessment showed decreased size of post-MI fibrosis in both-VEGF165- or HGF-treated animals yet most prominent reduction of collagen deposition was observed in VEGF165+HGF group. Combined delivery group rats were the only to show significant increase of left ventricle (LV) wall thickness. We also found dilatation index improved in HGF or VEGF165+HGF treated animals. These effects were partially supported by our findings of c-kit+ cardiac stem cell number increase in all treated animals compared to negative control. Sporadic Ki-67+ mature cardiomyocytes were found in peri-infarct area throughout study groups with comparable effects of VEGF165, HGF and their combination. Assessment of vascular density in peri-infarct area showed efficacy of both-VEGF165 and HGF while combination of growth factors showed maximum increase of CD31+ capillary density. To our surprise arteriogenic response was limited in HGF-treated animals while VEGF165 showed potent positive influence on a-SMA+ blood vessel density. The latter hinted to evaluate infiltration of monocytes as they are known to modulate arteriogenic response in myocardium. We found that monocyte infiltration was driven by VEGF165 and reduced by HGF resulting in alleviation of VEGF-stimulated monocyte taxis after combined delivery of these 2 factors. Changes of monocyte infiltration were concordant with a-SMA+ arteriole density so we tested influence of VEGF165 or HGF on endothelial cells (EC) that mediate angiogenesis and inflammatory response. In a series of in vitro experiments we found that VEGF165 and HGF regulate production of inflammatory chemokines by human EC. In particular MCP-1 levels changed after treatment by recombinant VEGF, HGF or their combination and were concordant with NF-κB activation and monocyte infiltration in corresponding groups in vivo. We also found that both-VEGF165 and HGF upregulated IL-8 production by EC while their combination showed additive type of response reaching peak values. These changes were HIF-2 dependent and siRNA-mediated knockdown of HIF-2α abolished effects of VEGF165 and HGF on IL-8 production. To conclude, our study supports combined gene therapy by VEGF165 and HGF to treat MI and highlights neglected role of pleiotropic effects of angiogenic growth factors that may define efficacy via regulation of inflammatory response and endothelial function.

Gene Therapy with Hepatocyte Growth Factor Improves Left Ventricular Systolic Function After Myocardial Infarction: A Systematic Review and Meta-analysis of Pig Models

Improvement of Heart Function in Postinfarct Heart Failure Swine Models after Hepatocyte Growth Factor Gene Transfer: Comparison of Low-, Medium- and High-Dose Groups

Angiogenin Gene Transfer Improves Left Ventricular Function in Rats with Myocardial Infarction

Recruitment of Stem Cells by Hepatocyte Growth Factor Via Intracoronary Gene Transfection in the Postinfarction Heart Failure

Raav-Mediated Angiogenin Gene Transfer Induces Angiogenesis and Modifies Left Ventricular Remodeling in Rats with Myocardial Infarction

Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease.

Treatment of chronical myocardial ischemia by adenovirus-mediated hepatocyte growth factor gene transfer in minipigs

Induction of Collateral Artery Growth and Improvement of Post-Infarct Heart Function by Hepatocyte Growth Factor Gene Transfer

Hepatocyte Growth Factor Gene Therapy for Ischemic Diseases

Hepatocyte growth factor and granulocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy.

HGF Percutaneous Endocardial Injection Induces Cardiomyocyte Proliferation and Rescues Cardiac Function in Pigs

Effects of Hepatocyte Growth Factor Overexpressed Bone Marrow‐derived Mesenchymal Stem Cells on Prevention from Left Ventricular Remodelling and Functional Improvement in Infarcted Rat Hearts

Effects of Adenovirus-Mediated Hepatocyte Growth Factor Gene Therapy on Postinfarct Heart Function: Comparison of Single and Repeated Injections

VEGF 165 and HGF Improving Cardiomyocyte Proliferation in Experimental Porcine After Myocardial Infarction

Experimental Research on Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor Directed by Ultrasound-Targeted Microbubble Destruction in Rats.

Adenoviral VEGF-DΔN ΔC gene therapy for myocardial ischemia

Hepatocyte Growth Factor Intervention to Reduce Myocardial Injury and Improve Cardiac Function on Diabetic Myocardial Infarction Rats.

Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction

Combined Use of Transmyocardial Stents with Gene Therapy in the Treatment of Acute Myocardial Infarction

Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial

[Effects of Hepatocyte Growth Factor Gene Transfer in Combination with Echocardiographic Destruction of Microbubbles in a Rat Model of Experimental Myocardial Infarction.].